Tyra Biosciences, Inc. Common Stock

TYRANASDAQUSD
26.64 USD
0.54 (1.99%)AT CLOSE (11:59 AM EDT)
26.08
0.56 (2.10%)
POST MARKET (AS OF 07:03 PM EDT)
Post Market
AS OF 07:03 PM EDT
26.08
0.56 (2.10%)
🔴Market: CLOSED
Open?$27.11
High?$27.79
Low?$26.41
Prev. Close?$27.18
Volume?1.5M
Avg. Volume?813.4K
VWAP?$26.98
Rel. Volume?1.83x
Bid / Ask
Bid?$10.70 × 200
Ask?$28.31 × 200
Spread?$17.61
Midpoint?$19.51
Valuation & Ratios
Market Cap?1.6B
Shares Out?59.5M
Float?28.1M
Float %?52.1%
P/E Ratio?N/A
P/B Ratio?4.09
EPS?-$2.20
Dividend?0.00%
Ex-Dividend?N/A

Tyra Biosciences, Inc. Common Stock (TYRA) is currently trading at $26.64. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics place TYRA at a fair price relative to peers.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Employees
87
Market Cap
1.6B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2021-09-15
Address
2656 STATE STREET
CARLSBAD, CA 92008
Phone: (619) 728-4760
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bullish(+1/3)
Medium-Term (Wave)? Bearish(-3/3)
Short-Term (Ripple)? Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
23
Short Sent.?
10
Piotroski F-Score?0/9Weak
Altman Z-Score?37.41Safe
Confidence?45%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?28.72%Squeeze Risk
Short Interest?8.1M
Days to Cover?12.7
Free Float28.1M
Avg Daily Volume637.7K
Settlement Date2026-05-15
Financial Health
Current Ratio?20.49Strong
Quick Ratio?20.49Strong
Cash Ratio?4.41Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A
P/B?
Peers
100
S&P
44
4.09FAIR
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
S&P
97
-10.5CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
S&P
5
-33.7%WEAK
ROA?
S&P
3
-31.7%WEAK
Cash Flow & Enterprise
FCF?$-102470000
Enterprise Value?$1.5B
Fundamentals ratios updated end of day